Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: Association with other clinical and laboratory parameters - 08/03/11
![](/templates/common/images/mail.png)
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/204e.gif)
pages | 4 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objective |
Asymmetric dimethylarginine (ADMA) has been associated with atherosclerosis, vascular diseases and, recently, also with arthritis including rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
Methods |
Serum ADMA, arginine and symmetric dimethylarginine (SDMA) levels were assessed by liquid chromatography in 61 AS and 26 osteoarthritis (OA) patients with no known cardiovascular disease.
Results |
Serum ADMA levels were significantly increased in AS compared to OA patients (0.95±0.17μM versus 0.70±0.25μM; p<0.001). There were no differences in serum arginine and SDMA levels. Serum ADMA levels also positively correlated with age (R=0.258; p=0.043), body mass index (R=0.368; p=0.003), erythrocyte sedimentation rate (R=0.329; p=0.009) and ADMA levels negative correlated with chest expansion (R=−0.251; p=0.04). No correlations were found between ADMA levels and disease duration, pain intensity, BASDAI, BASFI, BASMI, quality of life, CRP, HLA-B27 positivity, endothelial dysfunction or carotid atherosclerosis.
Conclusion |
ADMA may serve as a marker of systemic inflammation and may reflect functional immobility in AS. Further studies are needed to assess the possible role of ADMA in AS and AS-related vascular disease.
Le texte complet de cet article est disponible en PDF.Keywords : Ankylosing spondylitis, ADMA, Atherosclerosis, Cardiovascular disease
Plan
Vol 78 - N° 2
P. 184-187 - mars 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?